elosulfase alfa

CHEBI:CHEBI_752235

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

active_ingredient_name
ELOSULFASE ALFA
rxcui
1490052
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
active_ingredient_strength
5 mg/5mL
route
INTRAVENOUS
dosage_form
INJECTION, SOLUTION, CONCENTRATE
marketing_category
DRUG FOR FURTHER PROCESSING
marketing_start_date
20140214
package_marketing_start_date
14-FEB-14
labeler_name
BioMarin International Limited
manufacturer_name
BioMarin Pharmaceutical Inc.
pharm_class
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
pharm_class_cs
alpha-Glucosidases [CS]
nui
N0000175823
pharm_class_epc
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
generic_name
elosulfase alfa
brand_name
VIMIZIM
brand_name_base
VIMIZIM
product_ndc
71931-500
application_number
BLA125460
spl_id
4ca6eeb8-d338-4610-858e-4dcfb17ffdf8
package_ndc
68135-100-99
package_description
20000 mL in 1 BAG (68135-100-99)
unii
ODJ69JZG85
spl_set_id
0caa2565-12b2-0ad0-1f9a-273e81c3d4cc
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class